tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

PRLD Stock Latest News

Prelude Therapeutics Appoints Paul Scherer as Director
Company AnnouncementsPrelude Therapeutics Appoints Paul Scherer as Director
11d ago
8K
PRLD
Prelude Therapeutics Reports Q1 2025 Financial Results
PremiumCompany Announcements
Prelude Therapeutics Reports Q1 2025 Financial Results
2M ago
PRLD
Prelude Therapeutics Reports Strong Q1 2025 Financial Results
PremiumCompany Announcements
Prelude Therapeutics Reports Strong Q1 2025 Financial Results
2M ago
8K
PRLD
Prelude Therapeutics’ PRT3789 Shows Promising Selectivity in SMARCA2 Degradation, Justifying Buy Rating
PremiumRatings
Prelude Therapeutics’ PRT3789 Shows Promising Selectivity in SMARCA2 Degradation, Justifying Buy Rating
2M ago
PRLD
Prelude Therapeutics: Solid Financial Position and Promising Clinical Catalysts Amidst Risks
PremiumRatings
Prelude Therapeutics: Solid Financial Position and Promising Clinical Catalysts Amidst Risks
3M ago
PRLD
Prelude Therapeutics CEO buys $467K in common stock
PremiumThe FlyPrelude Therapeutics CEO buys $467K in common stock
3M ago
PRLD
Prelude Therapeutics Reports 2024 Financial Results
Premium
Company Announcements
Prelude Therapeutics Reports 2024 Financial Results
4M ago
PRLD
Prelude Therapeutics Reports 2024 Financial Results and Updates
Premium
Company Announcements
Prelude Therapeutics Reports 2024 Financial Results and Updates
4M ago
8K
PRLD
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
PremiumThe Fly
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
4M ago
PRLD
Prelude Therapeutics sees cash runway into 2Q26
PremiumThe Fly
Prelude Therapeutics sees cash runway into 2Q26
4M ago
PRLD
PRLD Earnings this Week: How Will it Perform?
PremiumPre-Earnings
PRLD Earnings this Week: How Will it Perform?
4M ago
PRLD
Prelude Therapeutics Appoints Bryant D. Lim as CFO
PremiumCompany Announcements
Prelude Therapeutics Appoints Bryant D. Lim as CFO
5M ago
8K
PRLD
Foghorn Therapeutics initiated with a Buy at B. Riley
PremiumThe FlyFoghorn Therapeutics initiated with a Buy at B. Riley
5M ago
FHTX
PRLD
Prelude Therapeutics presents first interim data from trial of PRT2527
Premium
The Fly
Prelude Therapeutics presents first interim data from trial of PRT2527
7M ago
PRLD
Prelude Therapeutics price target lowered to $4 from $7 at JMP Securities
Premium
The Fly
Prelude Therapeutics price target lowered to $4 from $7 at JMP Securities
7M ago
PRLD
Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health
PremiumCompany Announcements
Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health
7M ago
PRLD
Prelude Therapeutics Shows Strong Q3 2024 Financial Results
PremiumCompany Announcements
Prelude Therapeutics Shows Strong Q3 2024 Financial Results
8M ago
8K
PRLD
Prelude Therapeutics reports Q3 EPS (43c), consensus (47c)
PremiumThe Fly
Prelude Therapeutics reports Q3 EPS (43c), consensus (47c)
8M ago
PRLD
Prelude Therapeutics price target lowered to $1 from $3 at Barclays
PremiumThe Fly
Prelude Therapeutics price target lowered to $1 from $3 at Barclays
8M ago
PRLD
Prelude Therapeutics presents new data from Phase 1 trial of PRT3789
PremiumThe FlyPrelude Therapeutics presents new data from Phase 1 trial of PRT3789
8M ago
PRLD
Prelude announces publication of abstracts on SMARCA Degrader Programs
Premium
The Fly
Prelude announces publication of abstracts on SMARCA Degrader Programs
9M ago
PRLD
Playtika to acquire SuperPlay, Intel says not selling Mobileye: Morning Buzz
Premium
The Fly
Playtika to acquire SuperPlay, Intel says not selling Mobileye: Morning Buzz
9M ago
T
ME

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >